Key result
Functional Fas deficiency reduces myocardial infarct size by ~62% after ischemia-reperfusion.
Answers are grounded in this paper and cite their sources.
Fas is a widely expressed cell surface receptor that can initiate apoptosis when activated by its ligand (FasL). Whereas Fas abundance on cardiac myocytes increases in response to multiple pathological stimuli, direct evidence supporting its role in the pathogenesis of heart disease is lacking. Moreover, controversy exists even as to whether Fas activation induces apoptosis in cardiac myocytes. In this study, we show that adenoviral overexpression of FasL, but not beta-galactosidase, results in marked apoptosis both in cultures of primary neonatal cardiac myocytes and in the myocardium of intact adult rats. Myocyte killing by FasL is a specific event, because it does not occur in lpr (lymphoproliferative) mice that lack functional Fas. To assess the contribution of the Fas pathway to myocardial infarction (MI) in vivo, lpr mice were subjected to 30 min of ischemia followed by 24 h of reperfusion. Compared with wild-type mice, lpr mice exhibited infarcts that were 62.3% smaller with 63.8% less myocyte apoptosis. These data provide direct evidence that activation of Fas can induce apoptosis in cardiac myocytes and that Fas is a critical mediator of MI due to ischemia-reperfusion in vivo.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2003) studied Myocardial infarction due to ischemia-reperfusion. Functional Fas deficiency (lpr mice) and adenoviral FasL overexpression vs. Wild-type mice and adenoviral beta-galactosidase control was evaluated on Myocardial infarct size and cardiac myocyte apoptosis (62.3% smaller infarct size; 63.8% less myocyte apoptosis). Functional Fas deficiency in lpr mice reduced myocardial infarct size by 62.3% and myocyte apoptosis by 63.8% compared with wild-type mice after ischemia-reperfusion.
Synapse has enriched 10 related papers. Consider them for comparative context: